207 related articles for article (PubMed ID: 33436929)
1. Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions.
Brancato V; Aiello M; Basso L; Monti S; Palumbo L; Di Costanzo G; Salvatore M; Ragozzino A; Cavaliere C
Sci Rep; 2021 Jan; 11(1):643. PubMed ID: 33436929
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
3. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
4. Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis.
Lim CS; Abreu-Gomez J; Thornhill R; James N; Al Kindi A; Lim AS; Schieda N
Abdom Radiol (NY); 2021 Dec; 46(12):5647-5658. PubMed ID: 34467426
[TBL] [Abstract][Full Text] [Related]
5. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions.
Hectors SJ; Chen C; Chen J; Wang J; Gordon S; Yu M; Al Hussein Al Awamlh B; Sabuncu MR; Margolis DJA; Hu JC
J Magn Reson Imaging; 2021 Nov; 54(5):1466-1473. PubMed ID: 33970516
[TBL] [Abstract][Full Text] [Related]
9. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
[TBL] [Abstract][Full Text] [Related]
10. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis.
Junker D; Quentin M; Nagele U; Edlinger M; Richenberg J; Schaefer G; Ladurner M; Jaschke W; Horninger W; Aigner F
World J Urol; 2015 Jul; 33(7):1023-30. PubMed ID: 25081011
[TBL] [Abstract][Full Text] [Related]
12. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
[TBL] [Abstract][Full Text] [Related]
13. Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature.
Zhang L; Zhe X; Tang M; Zhang J; Ren J; Zhang X; Li L
Contrast Media Mol Imaging; 2021; 2021():7830909. PubMed ID: 35024015
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters.
Woźnicki P; Westhoff N; Huber T; Riffel P; Froelich MF; Gresser E; von Hardenberg J; Mühlberg A; Michel MS; Schoenberg SO; Nörenberg D
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630787
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric MRI Apparent Diffusion Coefficient (ADC) Accuracy in Diagnosing Clinically Significant Prostate Cancer.
Pepe P; D'Urso D; Garufi A; Priolo G; Pennisi M; Russo G; Sabini MG; Valastro LM; Galia A; Fraggetta F
In Vivo; 2017; 31(3):415-418. PubMed ID: 28438871
[TBL] [Abstract][Full Text] [Related]
16. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.
Ullrich T; Quentin M; Arsov C; Laqua N; Abrar D; Hiester A; Albers P; Antoch G; Schimmöller L
Rofo; 2020 May; 192(5):441-447. PubMed ID: 31622990
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric MRI and auto-fixed volume of interest-based radiomics signature for clinically significant peripheral zone prostate cancer.
Bleker J; Kwee TC; Dierckx RAJO; de Jong IJ; Huisman H; Yakar D
Eur Radiol; 2020 Mar; 30(3):1313-1324. PubMed ID: 31776744
[TBL] [Abstract][Full Text] [Related]
19. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
Choi MH; Kim CK; Lee YJ; Jung SE
AJR Am J Roentgenol; 2019 Apr; 212(4):839-846. PubMed ID: 30779662
[TBL] [Abstract][Full Text] [Related]
20. Radiomics Based on MRI as a Biomarker to Guide Therapy by Predicting Upgrading of Prostate Cancer From Biopsy to Radical Prostatectomy.
Zhang GM; Han YQ; Wei JW; Qi YF; Gu DS; Lei J; Yan WG; Xiao Y; Xue HD; Feng F; Sun H; Jin ZY; Tian J
J Magn Reson Imaging; 2020 Oct; 52(4):1239-1248. PubMed ID: 32181985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
